Phase-II Study of Docetaxel, Estramustine Phosphate, and Carboplatin in Patients with Hormone-Refractory Prostate Cancer
Authors:
- Shinji UrakamiSUShinji Urakami
- Shigeru NakamuraSNShigeru Nakamura
- Takeo HiraokaTHTakeo Hiraoka
- Taijyu HyugaTHTaijyu Hyuga
- Naoko ArichiNANaoko Arichi
- Kouji WakeKWKouji Wake
- Masahiro SumuraMSMasahiro Sumura
- Tatsuaki YonedaTYTatsuaki Yoneda
- Hirofumi KishiHKHirofumi Kishi
- Kazushi ShigenoKSKazushi Shigeno
- Hiroaki ShiinaHSHiroaki Shiina
- 1 May 2007
- journal article
- Published by Elsevier in European Urology
- Vol. 51 (5) , 1252-1258
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Management of the Spectrum of Hormone Refractory Prostate CancerEuropean Urology, 2006
- Pre-Treatment Nomogram for Disease-Specific Survival of Patients with Chemotherapy-Naive Androgen Independent Prostate CancerEuropean Urology, 2006
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor support in patients with hormone‐refractory prostate carcinomaCancer, 2003
- Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinomaCancer, 2003
- Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate CancerJournal of Urology, 2002
- Effect of carboplatin on response and palliation in hormone-refractory prostate cancerSupportive Care in Cancer, 1998
- CarboplatinDrugs, 1989
- Estramustine‐induced mitotic arrest in two human prostatic carcinoma cell lines du 145 and PC‐3The Prostate, 1984